摘要
目的分析比对单一二甲双胍用药方案与联合利拉鲁肽用药治疗肥胖2型糖尿病患者血糖各项指标改善情况,并作出评价。方法抽取2013年1月—2014年1月间(依照糖尿病2型诊断标准)该院救治的100例2型糖尿病患者。随机分组为对照组与实验组各50例。比照对照组(单一用药二甲双胍)与联合用药(二甲双胍+利拉鲁肽)血糖各项指标改善情况,进行评价。结果经研究,结果显示:在FBG、PBG、ISI、HbAIC、BMI5项指标数据对比上,治疗后,在实验组数据分别为7.30、10.90、-3.66、8.44、27.81,明显优于对照组治疗后9.41、12.31、-4.01、8.95、28.72。差异有统计学意义。结论合用比单一使用二甲双胍的药效,更加持久且高效。即基于肠促胰素系统的新机制降糖药利拉鲁肽具与二甲双胍合用,在不增加二甲双胍的用量的前提下,就可以有高效、持久的降糖效果。值得在临床上2型糖尿病的治疗中得以推广。
Objective To analyze the ratio of single and combined regimen of metformin drug liraglutide treatment of obesity in patients with type 2 diabetes,the glycemic index to improve the situation and to be evaluated.Methods Extraction January 2013between-2014 January（according to the diagnostic criteria for type 2 diabetes） in our hospital for treatment of 100 cases of type 2diabetes.Randomized to the control group and the experimental group,50 cases.Cf.the control group（metformin monotherapy） and combination therapy（metformin ＋ liraglutide） glycemic indexes to improve the situation,were evaluated.Results The main findings of the survey or study written,including representative and persuasive numerical results,can not talk about generalities.]：The study results show that：in the FBG,PBG,IS1,HbAIC,BM15 indicators data contrast,after treatment,the data in the experimental group were7.30,10.90,-3.66,8.44,27.81,significantly better than the control group after 9.41,12.31,-4.01,8.95,28.72.Significant differences,with statistical significance.Conclusion The combination of metformin efficacy than single use,more durable and efficient.That is a new mechanism of hypoglycemic agents with liraglutide incretin-based system in combination with metformin,metformin without increasing the amount of the premise,we can have efficient,long-lasting hypoglycemic effect.Deserve to be promoted in the clinical treatment of type 2 diabetes.
出处
《糖尿病新世界》
2015年第11期50-51,共2页
Diabetes New World Magazine
